Trial · NCT04157348
Results by group1,250
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,250
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 | Benralizumab 30 mg | 40 | Participants | ||
| Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 | Mepolizumab 300 mg | 40 | Participants | ||
| Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48 | Benralizumab 30 mg | 55 | Participants | ||
| Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48 | Mepolizumab 300 mg | 52 | Participants | ||
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | main remission / 0 week | 9 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | main remission / 0 week | 15 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | main remission / >0 to <12 weeks | 13 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | main remission / >0 to <12 weeks | 10 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | main remission / 12 to <24 weeks | 8 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | main remission / 12 to <24 weeks | 8 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | main remission / 24 to <36 weeks | 20 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | main remission / 24 to <36 weeks | 19 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | main remission / >=36 weeks | 20 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | main remission / >=36 weeks | 18 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | supportive remission / 0 week | 2 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | supportive remission / 0 week | 4 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | supportive remission / >0 to <12 weeks | 2 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | supportive remission / >0 to <12 weeks | 3 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Benralizumab 30 mg | supportive remission / 12 to <24 weeks | 5 | Participants | |
| Total Accrued Duration of Remission During DB Treatment Period | Mepolizumab 300 mg | supportive remission / 12 to <24 weeks | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04157348/results